Welcome to our dedicated page for ONCS news (Ticker: ONCS), a resource for investors and traders seeking the latest updates and insights on ONCS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ONCS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ONCS's position in the market.
OncoSec Medical has announced the launch of a Phase 2 study at the H. Lee Moffitt Cancer Center to evaluate the efficacy of its lead product, TAVO™, in combination with OPDIVO® for treating operable locally and regionally advanced melanoma. The study aims to assess whether TAVO can enhance the anti-tumor response of OPDIVO® when administered before surgical intervention. Significant improvements in relapse-free and overall survival have been noted with neoadjuvant therapies in current trials, positioning TAVO as a promising candidate for earlier-stage melanoma treatment.
OncoSec Medical (NASDAQ:ONCS) announced that CEO Daniel J. O'Connor will present at the LD 500 Virtual Conference on September 2, 2020, at 10:00 a.m. ET. The presentation will include a live Q&A session with investors. The conference runs from September 1-4, 2020, with O'Connor available for one-on-one meetings. OncoSec is focused on developing intratumoral cancer immunotherapies, particularly utilizing its lead candidate, TAVO™, to enhance immune response against tumors. More details can be found on OncoSec's investor website.
OncoSec Medical Incorporated (NASDAQ: ONCS) announced a public offering of 4,608,589 shares at $3.25 per share, generating approximately $15 million in gross proceeds. The offering is set to close on or about August 19, 2020. Proceeds will be utilized for clinical, regulatory, and manufacturing activities related to its product candidates, research and development, and general corporate purposes. ThinkEquity and Torreya Capital are the exclusive placement agents for this offering.
OncoSec Medical Incorporated (NASDAQ: ONCS) announced plans for a public offering of its common stock, subject to market conditions. The company intends to allocate the net proceeds towards clinical and regulatory activities, research and development, potential acquisitions, and general corporate purposes. Placement agents for the offering include ThinkEquity and Torreya Capital. The offering is backed by an effective Form S-3 registration statement with the SEC. Further details will be available in a preliminary prospectus supplement.
OncoSec Medical (NASDAQ: ONCS) announced that CEO Daniel J. O'Connor will present at the BTIG Virtual Biotechnology Conference on August 11, 2020, at 12:30 PM ET. The presentation will be available via webcast. OncoSec focuses on developing late-stage intratumoral cancer immunotherapies, particularly its lead product candidate TAVO™, which utilizes electroporation to deliver IL-12 for cancer treatment. The company is evaluating TAVO in combination with KEYTRUDA® in pivotal trials for metastatic melanoma and triple-negative breast cancer.
OncoSec Medical Incorporated (NASDAQ:ONCS) announced the promotion of Kellie Malloy Foerter to Chief Operating Officer, effective immediately. Formerly the Chief Clinical Development Officer, Foerter will now oversee finance, engineering, and HR, while maintaining her leadership in clinical operations, particularly the KEYNOTE-695 study for TAVO™ in metastatic melanoma. With nearly 30 years in clinical research, Foerter's expertise is expected to drive operational success and value for shareholders during a crucial growth period.
OncoSec Medical (NASDAQ:ONCS) announced that its COVID-19 vaccine candidate, CORVax12, was highlighted on KGW NewsChannel 8's 'Straight Talk'. This novel vaccine aims to prevent COVID-19 and is a collaboration with Providence Cancer Institute. They have filed an IND Application with the FDA for a phase 1 clinical trial involving healthy adults. CORVax12 combines OncoSec’s TAVO technology with a SARS-CoV-2 component, aiming to elicit a strong immune response through a multi-faceted approach.
OncoSec Medical, a developer of cancer immunotherapies, will join the Russell Microcap Index effective June 29, 2020. This inclusion highlights the company's advancements, particularly in its KEYNOTE-695 study for metastatic melanoma. Daniel J. O'Connor, the CEO, emphasized that this membership will enhance visibility and potentially increase shareholder value during a pivotal year for OncoSec. Russell indexes are benchmarked globally, with around $9 trillion in assets tied to them, offering significant exposure to institutional investors.
OncoSec Medical presented new data at the AACR Virtual Annual Meeting II demonstrating the efficacy of its next-generation TAVOPLUS IL-12 plasmid when combined with various T cell stimulators. These approaches showed promise for enhancing anti-tumor activity in solid tumors, potentially leading to an Investigational New Drug application. Key findings included improvements in T cell engagement, memory T cell expression, and tumor microenvironment remodelling, suggesting significant advancements in cancer immunotherapy.